Abstract
In this chapter we distinguish the use of predictive biomarkers from surrogate endpoint biomarkers. We also distinguish the use of predictive biomarkers for selecting patients for pivotal clinical trials of a new drug from the use of predictive biomarkers for optimizing the utilization of an existing drug. We summarize the key steps in the development of predictive biomarker classifiers for use in new drug development. We discuss the design of targeted clinical trials in which a predictive biomarker classifier is used to restrict entry, and present results comparing the efficiency of targeted trials relative to standard randomized pivotal trials. We also discuss alternative designs in which the predictive biomarker classifier is not used to restrict entry of patients but is used to prospectively define an analysis plan for evaluating the new drug in classifier negative and positive patients. The development of predictive biomarker classifiers can be subjective, but pivotal trials should test hypotheses about the effectiveness of a new drug in subsets defined in a completely prespecified manner by a predictive classifier, and should not contain any subjective components. The data used to develop the predictive classifier should be distinct from the data used to evaluate a new drug in subsets determined by the classifier. The purpose of the pivotal trial is to evaluate the new drug in patient groups defined prospectively by the predictive classifier, not to refine or reevaluate the classifier or its components. New drug development should move from a correlative science mode to a predictive medicine mode.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Torri V, Simon R, Russek-Cohen E, Midthune D, Freidman M (1992) Relationship of response and survival in advanced ovarian cancer patients treated with chemotherapy. J Natl Cancer I 84:407.
Burzykowski T, Molenberghs G, Buyse M, Geys H, Renard D (2001) Validation of surrogate endpoints in multiple randomized clinical trials with failure time end points. J Roy Stat Soc C-App 50(4):405
Korn EL, Albert PS, McShane LM (2004) Assessing surrogates as trial endpoints using mixed models. Stat Med 24:163–182
Golub TR, Slonim DK, Tamayo P et al (1999) Molecular classification of cancer: class discovery and class prediction by gene expression modeling. Science 286:531–537
Radmacher MD, McShane LM, Simon R (2002) A paradigm for class prediction using gene expression profiles. J Comput Biol 9:505–511
Simon RM, Korn EL, McShane LM, Radmacher MD, Wright GW, Zhao Y (2003) Design and analysis of DNA microarray investigations. Springer, New York
Ramaswamy S, Tamayo P, Rifkin R et al (2001) Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A 98(26):15149–15154
Hand DJ, Yu K (2001) Idiot's Bayes—not so stupid after all? Int Stat Rev 69(3):385–98.
Khan J, Wei JS, Ringner M et al (2001) Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 7(6):673–679
Simon R, Radmacher MD, Dobbin K, McShane LM (2003) Pitfalls in the analysis of DNA microarray data: class prediction methods. J Natl Cancer I 95:14–18
Dupuy A, Simon R (2007) Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. (Submitted for publication) 99:147–57.
Tibshirani R, Hastie T, Narasimhan B, Chu G (2002) Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 99(10):6567–6572
Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y (2007) Analysis of gene expression data using BRB-ArrayTools. Cancer Informat 2:11–17
Simon R (2003) Using DNA microarrays for diagnostic and prognostic prediction. Expert Rev Mol Diagn 3(5):587–595
Simon R (2003) Diagnostic and prognostic prediction using gene expression profiles in high dimensional microarray data. Brit J Cancer 89:1599–1604
Simon R (2005) A roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 23:7332–7341
Freidlin B, Simon R (2005) Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res 11:7872–7878
Simon R, Maitournam A (2004) Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 10:6759–6763
Simon R, Maitournam A (2006) Correction & Supplement: Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 12:3229
Maitournam A, Simon R (2005) On the efficiency of targeted clinical trials. Stat Med 24:329–339.
Simon R, Maitnourim A (2006) Evaluating the efficiency of targeted designs for randomized clinical trials: Supplement and Correction. Clin Cancer Res 12:3229
Simon R, Wang SJ (2006) Use of genomic signatures in therapeutics development. Pharmacogenomics J 6:1667–1673
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Simon, R. (2008). Predictive Biomarker Classifiers in the Design of Pivotal Clinical Trials. In: Cohen, N. (eds) Pharmacogenomics and Personalized Medicine. Methods in Pharmacology and Toxicology. Humana Press. https://doi.org/10.1007/978-1-59745-439-1_11
Download citation
DOI: https://doi.org/10.1007/978-1-59745-439-1_11
Publisher Name: Humana Press
Print ISBN: 978-1-934115-04-6
Online ISBN: 978-1-59745-439-1
eBook Packages: Springer Protocols